Where does TheraVida, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), TheraVida, Inc. ranks #27,635 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does TheraVida, Inc. hold?

TheraVida, Inc. holds 10 US utility patents granted between 2015 and 2023, spanning 3 technology areas.

What is TheraVida, Inc.'s Innovation Score?

TheraVida, Inc. has an Innovation Score of 29.2 out of 100 (30th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does TheraVida, Inc. focus on?

TheraVida, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 10 patents, ranking #1,884 of 6,058 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

Is TheraVida, Inc.'s patent grant rate increasing or decreasing?

TheraVida, Inc.'s recent grant velocity is -33% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for TheraVida, Inc.'s patents?

TheraVida, Inc.'s patents average 21.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the TheraVida, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

TheraVida, Inc.

USPTO PatentsView assignee record - 10 granted patents across 3 technology areas, recorded in grant years 2015–2023. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Theravida ranks #27,635 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 3 technology areas.

#27,635
of 49,997 US assignees by volume: 30th percentile
by Innovation Score (29.2/100): 21.9
avg claims per patent: -33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R27635 · US Corporation #27,635 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #27,635/49,997
PHOTO-FINISH The United States…
CPC-NARROW A61P · 3 areas
INNOV-THIN 29.2/100
CLAIMS-DENSE 21.9 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: The United States Government represented by the Department of Veterans Affairs (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Theravida’s 29.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (28%) Velocity 1.7 pts (6%) Breadth 6.1 pts (21%) Claim depth 13.1 pts (45%)

Qualcomm Incorporated · highest

85
TheraVida · this assignee

29
3D Lighting… · lowest

7

What this shows Theravida's Innovation Score is 29.2/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Theravida?

Each dot is one of Theravida’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Theravida’s own 21.9 claims/patent is ABOVE the 14.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Theravida vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Theravida's grants concentrate

TheraVida, Inc. is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (2 grants) versus a trough of 1 in 2016. By volume, Theravida sits between The United States Government represented by the Department of Veterans Affairs and Thermodyn SAS.

Theravida's three-year grant acceleration

TheraVida, Inc. shows 1 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

The United States…

10
The United States…

10
The United States…

10
The Upper Deck

10
Therma-tru

10
Thermo Electron M…

10
Thermocompact

10
Thermodyn SAS

10
Theravida ◀

10

What this shows TheraVida holds 10 patents at rank #27,657, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near TheraVida

By rank, the assignees closest to #27,657 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in TheraVida's primary technology class.

Theravida's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

29 30th percentile higher than 30% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2023

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

TheraVida, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	20.0%
2016	1	10.0%
2017	1	10.0%
2018	1	10.0%
2019	1	10.0%
2020	2	20.0%
2021	1	10.0%
2023	1	10.0%

Which technologies does TheraVida, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 10

Y02A - Technologies FOR Adaptation TO Climate Change 4

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

TheraVida, Inc.'s patent record in context - here's where to go next.

TheraVida, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #27,635 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare TheraVida, Inc. against The United States Government represented by the Department of Veterans Affairs, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 29.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.